Lindsey Wahlstrom spent more than ten years working in patient recruitment, engagement, and research before her five-year-old daughter Rona was diagnosed with a rare disease. What followed reshaped everything she thought she understood about trial participation. The family enrolled in four clinical trials together. Lindsey served as Rona’s stem cell donor. Rona did not survive her treatment. Wahlstrom has since co-founded Rona’s Fun Lab and trademarked the title Chief Momatologist™, a term hospital residents coined, not entirely as a compliment, for the mother who would not stop asking questions. For sponsors, CROs, and site operators who have grown comfortable treating patient centricity as a communications posture rather than an operational commitment, her answers are worth reading slowly.


Lindsey Wahlstrom, Co-founder and Chief Momatologist, Rona's Fun Lab
Lindsey Wahlstrom, Co-founder and Chief Momatologist, Rona’s Fun Lab

Moe: How did your professional understanding of trial participation break down once you became a participant yourself?

Lindsey Wahlstrom: I was working in medical research for a long time, and then my perfectly healthy five-year-old was diagnosed with a rare disease. To make a very long and winding road short, we ended up participating in four clinical trials together. I was her stem cell donor. We did two stem cell-based studies and two T-cell-based studies using my cells to fight infections. Unfortunately, she didn’t survive her treatment.

One of the biggest takeaways is that not everyone will survive. That sounds like it shouldn’t be revelatory, but I think most of us at conferences see the child who did survive or the person whose treatment did work. Often that’s not the case. We really need to start thinking about how to balance the magic of science, which is our tagline, with the magic of living. How do we build that into our protocols and our schedules of activities?

The other key thing is how we assess burden. When we think about burden in a protocol, we’re thinking about it from the perspective of our trial: how many site visits, how many medications. But the baseline level of burden someone is already carrying when they’re navigating a health condition for themselves or a loved one is higher than what the average person is dealing with. We need to start thinking about burden more holistically, and how we ensure we aren’t adding burden onto families without some level of reciprocity, whether that’s in data, access to treatment, or really making space for them to control for quality of life in the research setting.


Moe: How do you recognize a protocol that had genuine patient input versus one that only went through the motions?

Lindsey: There’s a difference between engaging patients for the sake of engaging them and engaging someone prior to protocol lock, when that engagement can actually lead to a change. Either you’re finding out what’s going to be hard about the protocol you’ve written, or you’re actually writing a protocol that might be more successful with the community.

I’ve seen protocols looking at three or four heart biopsies when you really only need two, at the start and the end of the study. That’s not a tiny procedure. When you engage people with lived experience from the beginning, you tend to see that reflected in the burden. It’s one thing to understand a procedure name in a protocol on an intellectual level. It’s a very different thing to understand what that means in practice.

Even something as simple as a blood draw: in a community that has frequent blood draws, where veins are blown or scarred and hard to access due to chemo, you might see more systematic scheduling, better alignment of activities to standards of care, instead of asking people for more data just for the sake of data. I would really encourage people to question anything added in for potential future exploration, and to control tightly for what you’re actually looking at.

“It’s one thing to understand a procedure name in a protocol on an intellectual level. It’s a very different thing to understand what that means in practice.”


Moe: How did genuine understanding actually look in the informed consent process, from the inside?

Lindsey: I don’t know that I had it done well, and I think that’s why this one really jumps out to me.

I had read hundreds of protocols and informed consent forms beyond the two hundred or so studies I had worked on. Ours was almost thirty pages long. I read it multiple times before we signed it. I was still blindsided by what happened, because I didn’t fully understand what specific terms meant.

Ensuring understanding isn’t about the form. It’s about whether we’re on the same page, and whether a family can feed that back in a way that really communicates that they understand it.

ICFs are so often written for regulators or heavily edited by compliance teams. When we talk about patient-centric ICFs, the conversation is always about making them shorter or interactive. I actually like more interactive ICFs. My dream is a process that extends throughout the duration of the trial, with modules that surface definitions as things arise, so families can refamiliarize themselves with components that are critical to understand for where they’re at. Because most studies aren’t going to hit their endpoints. And even if they do, you’re going to have folks on the control arm. Things are going to come up.

I had what I’d describe as a weird kind of trauma around our ICF. I signed it essentially four times across four studies. The first time, I had sixty minutes of really technical questions about long-term side effects of medications. By the fourth time, I had one question: is it going to work? The answer wasn’t yes. It was: it’s her best chance.

In that moment, a human was really critical. I think there are fantastic ways to use technology on that first part, ensuring people have a baseline level of understanding coming into the ICF discussion, so you can actually have a conversation around what the study means for them in that particular instance and have time for questions. How do we ensure people come in prepared, ready to have that conversation, and then have access to a human when they need it?


Moe: Why is “balance” the principle that sponsors and CROs are furthest from delivering, and what single change would close that gap?

Lindsey: Balance is the big one for me, always. The single greatest change on the sponsor or CRO side is this: in tech, we start designing for patients as the end user. But then we’re speaking more to the sponsor, or to data vendors, or to other recruitment firms, and all of a sudden the best of intentions shifted. I am prioritizing the requirements of the people I’m working with more regularly, and I have lost the thread with the patient.

Sites and patients are on the front line of research. If we can design for those two stakeholders, and take on the hard work ourselves of the things that are hard about our jobs, we would be better off. A lot of the work at sites is really hard. A lot of what patients are dealing with is really hard. If we can figure out our own systems so that people feel those hiccups less, and not pass our hard work onto people who are already doing hard stuff, we’d all be better off. It’s remembering that there are people behind the data points, people at the sites having a human experience, and smoothing out our processes so those two groups don’t feel it.


Moe: How do you tell within minutes of walking into an organization whether patient centricity is real?

Lindsey: What they’re measuring. What their KPIs are. The things you measure are the things that matter most. That’s what people are designing their workdays and their targets around.

It’s really easy to tell when someone is paying lip service to patient centricity versus actually doing the work. Doing the hard work of engagement early and often, bringing in different voices and perspectives, site engagement included. It’s not just patient engagement. And you see it in the way protocols are written, the way documents are written, the processes behind those things.

If you don’t have KPIs tied to what you say you believe around patient centricity and engagement, I would question how big and how important it really is to you.


Moe: Where has technology helped families feel seen, and where has it made them feel processed?

Lindsey: Tech can be fantastic. In a rare disease setting especially: when Rona met another child with aplastic anemia, her condition, I will never forget that moment. It was on Zoom, because it’s a very rare condition, and that was the only way we could make it happen. We also had a virtual summer camp in the hospital for kids in protective isolation from cancer or a transplant setting. We used technology a lot to help her feel seen and included.

In terms of data capture and ePRO, there’s a real role for tech in ensuring people can answer those questions and are being asked them in a way that works for them, whether that’s an app, a text message, a call, whatever it needs to be.

But we need to remember there’s a human on the other side of it, and a human at the site, and a human in the room. In our case, we were in protective isolation. We couldn’t have other friends and family around. We really needed to rely on the care team for social interaction as well. Some of the role of technology needs to be about augmenting human interaction, creating space, not more burden, for the people on the ground to interact with families in a way that feels meaningful and builds the trust and connection that’s critical to study completion, data completeness, and keeping people from withdrawing due to a poor experience.

We really need to think about context, and look for opportunities to make things easier, not just add one more system for people to navigate while they’re trying to have a conversation with the person in front of them.

“These are folks who are giving very precious time, and sometimes some of their last days, to us in order to forward our research. We should be really mindful of that.”


Moe: Where did you see the gaps between sites, sponsors, and vendors in real time, and what did those gaps cost your family?

Lindsey: I was a little unique in that ours was a hospital-based consortium study across three hospitals. There wasn’t a large pharmaceutical or biotech company running it. But when I look at it through my professional lens, trust is the big thing.

Whenever there’s a small hiccup, whenever there’s a handoff to a new system or a new person, you risk losing that person. It can make someone feel processed instead of really looked after.

Navigation support can be really helpful, having a single point of contact who takes someone through the entire process. We had a clinical trial navigator, and she was great. I could send her an email and get a response early, and she helped me through all the appointments leading into our process. Having a human point of contact, someone available to answer questions, makes a real difference.

When systems and vendors don’t communicate, we lose trust and waste people’s time. These are folks who are giving very precious time, and sometimes some of their last days, to us in order to forward our research. We should be really mindful of that, and find an equilibrium there.


Lindsey Wahlstrom is co-founder and Chief Momatologist™ at Rona’s Fun Lab.

Website | + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.